For the second day, with the good news regarding the presidential election being settled and a promising vaccine on the move, the market again responded by enthusiastically moving away from the pandemic-benefiting tech stocks to the more traditional value stocks. The sentiment is that if the economy can reopen sooner rather than later the “stay-at-home” stocks won’t be as valuable. Amazon, Facebook and Microsoft all fell while the S&P value index gained 1.3 percent. Investors have by and large been ignoring Trump’s election outcome complaints. The only downside to the news is that the vaccine progress dims the prospects for another multi-trillion dollar relief bill, something small businesses and the unemployed desperately need. With the Dow boosted another 262 points, volume was again way above average at 12.6 billion.
TUE NOVEMBER 10, 2020 6:23 PM
Nasdaq retreats as technology stocks
lose favor
DJ: 29,157.97 +834.57 NAS: 11,713.78 -181.45 S&P: 3,550.50 +41.06 11/9
DJ: 29,420.92 +262.95 NAS: 11,553.86 -159.93 S&P: 3,545.53
-4.97 11/10
NEW
YORK (Reuters) - The Nasdaq closed 1.4% lower and the S&P dipped slightly
on Tuesday as investors sold off technology stocks that benefited from virus
lockdowns, favoring sectors that have suffered most during the pandemic instead
on hopes a COVID-19 vaccine will turn the economy around. The heavyweight
technology .SPLRCT and
consumer discretionary sectors .SPLRCD fell
sharply and communication services .SPLRCL languished
while investors favored small caps and economically sensitive energy .SPNY and industrials .SPLRCI sectors
as well as value stocks in consumer staples .SPLRCS. The main U.S. indexes had hit intraday peaks
on Monday after Pfizer Inc PFE.N said a vaccine it is
developing with German partner BioNTech SE 22UAy.DE was
90% effective against COVID-19.
“It’s the reopening trade. To the extent the economy can
reopen sooner rather than later the stay-at-home stocks won’t be as valuable,”
said Jim Paulsen, chief investment strategist at The Leuthold Group in
Minneapolis.
The Dow
Jones Industrial Average .DJI rose 262.95 points,
or 0.9%, to 29,420.92, the S&P 500 .SPX lost 4.97 points, or
0.14%, to 3,545.53 and the Nasdaq Composite .IXIC dropped 159.93 points
to 11,553.86. In small caps, the S&P 600 index .SPCY rose 2.6%, however, and the Russell
2000 .RUT climbed
1.9%.
Amazon.com Inc AMZN.O, which finished down 3.5%, Facebook Inc FB.O, off 2.3%, and Microsoft MSFT.O, which fell 3.4%, extended Monday's losses and weighed
heavily on the tech-laden Nasdaq throughout the session. The stocks have boomed
during the virus induced work-from-home trend. After hitting a record in
Monday's session, the Philadelphia Semiconductor Index .SOX underperformed sharply on Tuesday,
finishing down 3%, with Nvidia NVDA.O, Advanced Micro Devices AMD.O and Xilinx XLNX.O all falling more than 6%.
And the S&P's value stock index .IVX, which tends to outperform coming out of a
recession, gained 1.3%
on Tuesday compared with a 1.15 decline for the less economically sensitive
growth index .IGX. “Everybody’s coming out of the woodwork saying the same thing
that now is the time to be
buying value” and selling technology said Robert Pavlik, senior
portfolio manager at Dakota Wealth in Fairfield, Connecticut. “People believe the Pfizer vaccine is going to initiate a
reopening of the economy forcing people back on the road, back to work
and back into the stores,” said Pavlik. “There’s some warrant to it but to see
this kind of action is extreme.”
Trading was also choppy at times as some
investors monitored for election uncertainty after U.S. Secretary of State Mike
Pompeo became the latest Republican to suggest President Donald Trump would not
concede the White House to Democrat Joe Biden.
But Leuthold’s Paulsen said most market participants have priced in a
Biden win and have been largely ignoring the Trump administration’s election outcome complaints
because they have not produced evidence of problems with votes.
While President-elect Biden hailed the vaccine
progress he has cautioned that it would be “many more months” before it is widely available.
Meanwhile, daily new U.S. cases topped 100,000 for the sixth straight day. U.S. Health Secretary Alex Azar said on
Tuesday that if Pfizer submits its interim COVID-19 vaccine to health
regulators as quickly as expected, the U.S. government expects to start
vaccinations in December. A vaccine
breakthrough may weaken the case for another large U.S. fiscal stimulus bill,
although some investors say that relief is still needed for struggling
businesses. Senate Majority Leader Mitch
McConnell, a
Republican, said on Tuesday he saw no need for a multitrillion-dollar coronavirus relief bill.
Intel INTC.O and Apple Inc AAPL.O both closed lower after Apple introduced
its first notebook computer with an Apple-designed microprocessor.
Advancing issues outnumbered declining
ones on the NYSE by a 1.80-to-1 ratio; on Nasdaq, a 1.53-to-1 ratio favored
advancers. The S&P 500 posted 11 new
52-week highs and no new lows; the Nasdaq Composite recorded 80 new highs and
20 new lows.
On
U.S. exchanges 12.61 billion shares changed hands compared with the 9.88 billion average from the
last 20 sessions though Tuesday’s volume was well below Monday’s 17.35 billion
tally.
No comments:
Post a Comment